402 related articles for article (PubMed ID: 20489416)
21. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
22. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
Ferrières J; Bérard E; Crisan O; Bongard V
Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
[TBL] [Abstract][Full Text] [Related]
23. A case report of a diabetic woman with very low HDL cholesterol.
Chaychi L; Kinlaw WB; Asztalos BF; Schaefer EJ
J Clin Lipidol; 2010; 4(2):133-5. PubMed ID: 21122641
[No Abstract] [Full Text] [Related]
24. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
[TBL] [Abstract][Full Text] [Related]
25. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
26. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
27. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Schima SM; Maciejewski SR; Hilleman DE; Williams MA; Mohiuddin SM
Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
[TBL] [Abstract][Full Text] [Related]
29. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
30. Is lipid control necessary in hemodialysis patients?
Cheung AK
Clin J Am Soc Nephrol; 2009 Dec; 4 Suppl 1():S95-101. PubMed ID: 19996012
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
32. What is the most effective strategy for managing diabetic dyslipidaemia?
Reasner CA
Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
[TBL] [Abstract][Full Text] [Related]
33. High-density lipoprotein cholesterol: current perspective for clinicians.
Whayne TF
Angiology; 2009; 60(5):644-9. PubMed ID: 19240106
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of dyslipidemia in clinical practice].
Paragh G; Harangi M
Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
[TBL] [Abstract][Full Text] [Related]
35. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
36. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
37. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
38. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
Toth PP
Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
[TBL] [Abstract][Full Text] [Related]
39. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register.
Eriksson M; Zethelius B; Eeg-Olofsson K; Nilsson PM; Gudbjörnsdottir S; Cederholm J; Eliasson B
Eur J Cardiovasc Prev Rehabil; 2011 Feb; 18(1):97-105. PubMed ID: 21354969
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
